Literature DB >> 35239445

Late Recurrence Following Early Breast Cancer.

Alexandra Thomas1, Heather A Parsons2, Karen Lisa Smith3.   

Abstract

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in the Journal of Clinical Oncology, to patients seen in their own clinical practice.

Entities:  

Mesh:

Year:  2022        PMID: 35239445      PMCID: PMC9061154          DOI: 10.1200/JCO.22.00167

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   50.717


  20 in total

1.  Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.

Authors:  Elisabeth Trapp; Wolfgang Janni; Christian Schindlbeck; Julia Jückstock; Ulrich Andergassen; Amelie de Gregorio; Marianna Alunni-Fabbroni; Marie Tzschaschel; Arkadius Polasik; Julian G Koch; Thomas W P Friedl; Peter A Fasching; Lothar Haeberle; Tanja Fehm; Andreas Schneeweiss; Matthias W Beckmann; Klaus Pantel; Volkmar Mueller; Brigitte Rack; Christoph Scholz
Journal:  J Natl Cancer Inst       Date:  2019-04-01       Impact factor: 13.506

2.  Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Joseph Sparano; Anne O'Neill; Katherine Alpaugh; Antonio C Wolff; Donald W Northfelt; Chau T Dang; George W Sledge; Kathy D Miller
Journal:  JAMA Oncol       Date:  2018-12-01       Impact factor: 31.777

3.  Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

Authors:  Harold J Burstein; Christina Lacchetti; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen A Gelmon; Sharon H Giordano; Clifford A Hudis; Alexander J Solky; Vered Stearns; Eric P Winer; Jennifer J Griggs
Journal:  J Clin Oncol       Date:  2018-11-19       Impact factor: 44.544

4.  Factors associated with breast cancer mortality after local recurrence.

Authors:  R Dent; A Valentini; W Hanna; E Rawlinson; E Rakovitch; P Sun; S A Narod
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

Review 5.  Clinical management and biology of tumor dormancy in breast cancer.

Authors:  Stefan Werner; Isabel Heidrich; Klaus Pantel
Journal:  Semin Cancer Biol       Date:  2021-02-11       Impact factor: 15.707

6.  Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

Authors:  Mitch Dowsett; Ivana Sestak; Meredith M Regan; Andrew Dodson; Giuseppe Viale; Beat Thürlimann; Marco Colleoni; Jack Cuzick
Journal:  J Clin Oncol       Date:  2018-04-20       Impact factor: 44.544

7.  The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis.

Authors:  Rikke Nørgaard Pedersen; Buket Öztürk Esen; Lene Mellemkjær; Peer Christiansen; Bent Ejlertsen; Timothy Lee Lash; Mette Nørgaard; Deirdre Cronin-Fenton
Journal:  J Natl Cancer Inst       Date:  2022-03-08       Impact factor: 13.506

8.  Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Ivana Sestak; Richard Buus; Jack Cuzick; Peter Dubsky; Ralf Kronenwett; Carsten Denkert; Sean Ferree; Dennis Sgroi; Catherine Schnabel; Frederick L Baehner; Elizabeth Mallon; Mitch Dowsett
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

9.  Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions.

Authors:  Ryan J O Dowling; Joseph A Sparano; Pamela J Goodwin; Francois-Clement Bidard; David W Cescon; Sarat Chandarlapaty; Joseph O Deasy; Mitch Dowsett; Robert J Gray; N Lynn Henry; Funda Meric-Bernstam; Jane Perlmutter; George W Sledge; Mangesh A Thorat; Scott V Bratman; Lisa A Carey; Martin C Chang; Angela DeMichele; Marguerite Ennis; Katarzyna J Jerzak; Larissa A Korde; Ana Elisa Lohmann; Eleftherios P Mamounas; Wendy R Parulekar; Meredith M Regan; Daniel Schramek; Vuk Stambolic; Timothy J Whelan; Antonio C Wolff; Jim R Woodgett; Kevin Kalinsky; Daniel F Hayes
Journal:  JNCI Cancer Spectr       Date:  2019-08-10

10.  Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy.

Authors:  Iris Noordhoek; Kai Treuner; Hein Putter; Yi Zhang; Jenna Wong; Elma Meershoek-Klein Kranenbarg; Marjolijn Duijm-de Carpentier; Cornelis J H van de Velde; Catherine A Schnabel; Gerrit-Jan Liefers
Journal:  Clin Cancer Res       Date:  2020-10-27       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.